D.C. Court Upholds FDA Classification Of CollaGenex' Periostat
This article was originally published in The Pink Sheet Daily
Executive Summary
D.C. federal judge agrees with FDA's argument that Periostat should be classified as an antibiotic since it contains the drug doxycycline, which was previously classified as an antibiotic. CollaGenex is seeking a separate injunction to prevent Ivax and CorePharma from marketing generic versions of the periodontal agent.
You may also be interested in...
FDA Approves Periostat Generics, But Launch Could Hinge On Patent Case
FDA approves three ANDAs for Periostat tablets and one for the capsule formulation. In a patent infringement lawsuit, Periostat marketer CollaGenex is requesting that a federal court preliminarily enjoin launches by Ivax and CorePharma.
FDA Approves Periostat Generics, But Launch Could Hinge On Patent Case
FDA approves three ANDAs for Periostat tablets and one for the capsule formulation. In a patent infringement lawsuit, Periostat marketer CollaGenex is requesting that a federal court preliminarily enjoin launches by Ivax and CorePharma.
Allergan Lawsuit Over Cyclosporine "Antibiotic" Classification Rejected
A drug may be classified as an "antibiotic," thereby exempting it from Waxman/Hatch exclusivity, even if its intended use is not fighting infectious disease, D.C. judge rules in Restasis case. Allergan says ruling will have "limited effect" because Restasis is patent-protected through 2014.